Assertio Therapeutics (ASRT) Stock Statistics & Valuation Metrics

Assertio Therapeutics has a market cap or net worth of $124.97M. The enterprise value is $153.87M.

Assertio Therapeutics has 6,445,161 shares outstanding. The number of shares has decreased by -2.65% in one year.

Assertio Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -15.22%.

The current PE Ratio of Assertio Therapeutics is ―. Assertio Therapeutics’s PEG ratio is -0.05.

In the last 12 months, Assertio Therapeutics had revenue of 118.71M and earned -29.50M in profits. Earnings per share was -4.74.

In the last 12 months, operating cash flow was -28.18M and capital expenditures 0.00, giving a free cash flow of -28.18M billion.

Assertio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Assertio Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).

Assertio Therapeutics as a current ratio of 1.70, with Debt / Equity ratio of 41.64%

In the past 12 months, Assertio Therapeutics has paid -435.00K in taxes.

Assertio Therapeutics EV to EBITDA ratio is 6.80, with an EV/FCF ratio of -3.09.

Assertio Therapeutics has $63.41M in cash and marketable securities with $39.12M in debt, giving a net cash position of $24.28M billion.

Gross margin is 70.19%, with operating margin of -18.14%, and net profit margin of -24.85%.

The average price target for Assertio Therapeutics is $38.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy